Introduction
============

Cancer stem cells (CSCs) are subpopulations of cancer cells which have capacity to propagate tumors *in vitro* and *in vivo*, and have characteristics of normal stem cells. It\'s reported that glioblastomas multiforme (GBMs) also have a subpopulation of stem-like cells which are responsible for glioma proliferation, chemo- and radiotherapy resistance, and tumor recurrence [@B1]-[@B4]. Therapies that do not eradicate the GSC compartment are likely to achieve little success.

Melatonin (N-acetyl-5-methoxytryptamine) is an indolamine derived from I-tryptophan which is secreted by the pineal gland. It is well documented that melatonin is involved in the regulation of chrono-biological rhythms and endocrine function[@B5]. Subsequently, many other functions of melatonin have been reported such as immune-enhancing, anti-inflammatory and antioxidant properties [@B6]-[@B8]. In recent years, increasing evidence have demonstrated that melatonin has inhibitory effects on many cancer types such as breast, colon and gastric cancer[@B9]-[@B11]. It is also reported that melatonin inhibited glioma cell proliferation both *in vitro*and *in vivo,* in relation to its inhibitory role in key intracellular effectors such as PKC, Akt, and NF-kB[@B12]. However, the effects and mechanism in which melatonin can inhibit GSCs is far from clarified. Less clear are the extent and nature of the regulatory network involved and how these might affect melatonin function.

EZH2 is one of the core components of polycomb group (PcG) proteins. It functions as a lysine methyl-transferase, especially to catalyze tri-methylation of histone 3 at lysine 27 (H3K27me3). In a wide range of cancers, including glioblastomas, elevated expression of EZH2 is well recognized and its expression is strongly linked to tumor malignancy, invasiveness and poor prognosis[@B13], [@B14]. Recent studies also suggested that up-regulation of EZH2 has been identified as a marker for GSCs, possibly reflecting its role in the maintenance of stem cells[@B15]. EZH2 signaling regulates proliferation and self-renewal of GSCs and protects them from radiation-induced cell death[@B3], [@B16]. EZH2 modulators, on the other hand, have been shown to influence the development of GSC niche and tumor growth[@B17], suggesting EZH2 as a potential therapeutic target to eradicate glioblastomas.

NOTCH receptors and ligands are single-pass transmembrane proteins that play an important role in cell fate decisions during embryonic and postnatal development[@B18]-[@B20]. NOTCH receptors are overexpressed in many kinds of cancers such as pancreatic, cervical, breast, colon and lung cancer[@B20]. Previous study showed that NOTCH1 was decreased EZH2 was suppressed in Pancreatic Tumor[@B21].

In the current study, we provided the first evidence showing that melatonin can inhibit viability and self-renewal of GSCs, which is correlated with a decrease in the expression of PcG protein EZH2. Furthermore, we have identified NOTCH1 as the key signal molecule that regulates the EZH2-mediated effects of melatonin in the GSCs. Taken together, our findings suggest that melatonin, as a blocker of EZH2-NOTCH1 signaling axis, may be used as a potential therapeutic agent to prevent glioma progression.

Materials and methods
=====================

Cell Lines, GSC culture and Tissue Samples
------------------------------------------

Glioblastoma cell lines (U251 and T98G) were obtained from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The Cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM; HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) at 37℃ with 5% CO2. Tumor-spheres were obtained from the U251 and T98G cells cultured in DMEM/F12 medium (HyClone, Logan, UT, USA) supplemented with 2% B27 (Invitrogen, Carlsbad, CA, USA), 25ng/ml human recombinant basic fibroblast growth factor (bFGF; R&D systems, Minneapolis, MN, USA), 25ng/ml epidermal growth factor (EGF; R&D systems, Minneapolis, MN, USA) and 1% penicillin/streptomycin (Gibco, Birmingham, MI, USA). Half of the sphere-forming medium was replaced every other day. 67 GBM specimens and 12 normal human brain specimens were obtained from the Department of Neurosurgery at Provincial Hospital affiliated to Shandong University. The study was approved by Shandong University Ethics Committee and all of the patients provided written informed consent.

Quantitative Real-time PCR (qRT-PCR)
------------------------------------

Trizol reagent (Gibco, Birmingham, MI, USA) was used for RNA extracting. Real-time ABI 7300 Fast Real-time PCR System (Applied Biosystems, Carlsbad, CA, USA) and SYBR Green PCR kit (Applied TaKaRa, Japan) were used for Real-time PCR [@B22]. The primer sequences are shown in Table [1](#T1){ref-type="table"}.

Cell viability assay
--------------------

Cell counting kit-8 (Dojindo, Japan) was used to monitor the proliferative viability of the cells. Briefly, 3000 cells were plated onto 96-well culture plates in a final volume of 100μL. After 48 hr, 10μL of CCK-8 solution was added into each well and incubated at 37℃ for 2 hr. The optical density of every sample was measured in a spectrophotometer at 450 nm. Experiments were repeated 6 times.

Immunohistochemistry (IHC)
--------------------------

Representative formalin-fixed and paraffin-embedded blocks were selected and cut into 5μm thick slices. IHC staining was performed using the standard avidin-biotin complex method. The primary antibodies used in the study were as follows: anti-EZH2 (Cell Signaling and Technology, Boston, MA, USA), anti-NOTCH1 (NOTCH intracellular domain 1, NICD1) (Cell Signaling and Technology, Boston, MA, USA). The staining scores were determined as previous method[@B23]. 0-4 scores were considered low expression an 6-16 scores were considered high expression.

Western Blotting
----------------

Wstern blotting was conducted as described[@B22]. The following primary antibodies were used: anti-CD133(Abgent, USA), anti-SOX2(Abgent, USA), anti-EZH2 (Cell Signaling and Technology, Boston, MA, USA), anti-NOTCH1 (NOTCH intracellular domain 1, NICD1) (Cell Signaling and Technology, Boston, MA, USA), anti-HES1 (Abcam, Cambridge, MA, USA) and anti-β-ACTIN (Zhongshan Golden Bridge Biotechnology, China).

Luciferase Reporter Assay
-------------------------

Luciferase reporter assay was conducted as previous method [@B22].

Chromatin Immunoprecipitation (CHIP)
------------------------------------

The GSC~U251~ were cross-linked with 1 % formaldehyde, quenched by adding 125 mM glycine and lysed in lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl, pH 8.1, 1mM PMSF). The chromatin was subsequently sonicated to generate DNA fragments between 200-600 bps. Cleared lysates were then diluted and incubated with the antibodies overnight at 4℃. The following antibodies were used to perform precipitation: anti-H3K27me3 (Cell Signaling and Technology, Boston, MA, USA), anti-EZH2 (Cell Signaling and Technology, Boston, MA, USA) and anti-SUZ12(suppressor of zeste 12) (Abcam, Cambridge, MA, USA). An isotype matched IgG was used as a negative control. Cross-linking of DNA fragments was reversed by pronase and subsequently incubated at 42℃ for 2 hr and 68℃ for 8 hr. The *NOTCH1* promoter DNA in the immunoprecipitates was detected by qRT-PCR. The following primers were used: F:5\'-TAGGTCCCTCCCAGCCTTT-3\'; R:5\'-GCTGATTTATTTCTCCACCACGA-3\'.

Plasmids and RNA interference
-----------------------------

Knockdown by small hairpin RNA (shRNA) was performed using GV248 vector (GeneChem, Shanghai, China) following the manufacturer\'s instructions. The following sequences were used: EZH2, 5\'-GAAATCTTAAACCAAGAAT-3\'; scramble, 5\'-TTCTCCGAACGTGTCACGT-3\'. Overexpression and reconstitution of EZH2 were achieved using GV230 vector (GeneChem, Shanghai, China). Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used to transfect the plasmids into the cells.

Statistical Analysis
--------------------

Quantitative data were expressed as mean ± standard deviation (SD). Significance was tested by one-way ANOVA or two-tailed t-test in various groups. Differences in proportions were evaluated by the Mann-Whitney U test. Spearman rank correlation analysis was used to analyze the correlation between EZH2 and NOTCH intracellular domain 1 (NICD1) expression. *P*\<0.05 was considered to be statistically significant.

Results
=======

Melatonin Inhibited Proliferation and Self-renewal Ability of GSCs
------------------------------------------------------------------

U251 and T98G glioblastoma cell lines were cultured in the stem cell enrichment medium (serum-free, supplemented with B27, bFGF and EGF) for more than 3 weeks until the diameter of the tumor-spheres reached to about 200μm (Figure [1](#F1){ref-type="fig"}A). We subsequently assessed the expression levels of CD133 and SOX2, two commonly-used GSC markers, in the glioma cell lines in comparison to the tumor-spheres derived from the respective cell line. The results showed that mRNA expressions of CD133 and SOX2 were significantly higher in the tumor-sphere cells (Figure [1](#F1){ref-type="fig"}B). These cells were then called the GSC~U251~ and GSC~T98G~ based on their origins and used in the following experiments.

To investigate the effect of melatonin on the viability of GSCs, CCK-8 assay was used to evaluate cell number of the GSC~U251~ and GSC~T98G~ treated with different concentrations of melatonin (0.1-1000μM). As shown in Figure [1](#F1){ref-type="fig"}C, melatonin inhibited viability of the GSCs in a dose-dependent manner (Figure [1](#F1){ref-type="fig"}C). Specifically, both 100μM and 1mM melatonin exerted notable growth-inhibitory effects on the GSC~U251~ and GSC~T98G~, even though the effect of 100μM on the GSC~T98G~ is rather moderate.

As mentioned previously, GSCs are characterized by their self-renewal ability. To test the effect of melatonin on GSC self-renewal, sphere-forming assay was performed. About 5×10^4^dissociated GSCs were planted in each sphere-forming medium supplemented with 100μM or 1mM melatonin. After 10 days, number of the tumor-spheres was counted. As the result depicted in Figure [1](#F1){ref-type="fig"}D, melatonin significantly decreased formation of the tumor-spheres (Figure [1](#F1){ref-type="fig"}D). In addition, both mRNA and protein expression levels of the GSC markers, CD133 and SOX2 were also decreased (Figures [2](#F2){ref-type="fig"}A and 2B), supporting a role of melatonin in the regulation of stem cell properties of GSCs.

EZH2 Was Involved in the Inhibitory Role of Melatonin in Regulation of GSC Properties
-------------------------------------------------------------------------------------

It is well documented that EZH2 plays vital roles in the maintenance of GSCs[@B17]. Thus, it was hypothesized that the involvement of melatonin in regulation of GSC properties may be linked to EZH2. To test this hypothesis, we first investigated the effect of melatonin on EZH2 expression in the GSC~U251~ and GSC~T98G~. The GSCs were treated with 1mM melatonin for 48 hr. qRT-PCR analysis indicated that the mRNA expression of EZH2 was significantly decreased in the melatonin-treated GSCs as compared with those without melatonin (Figure [2](#F2){ref-type="fig"}A). Correspondingly, EZH2 protein level was markedly reduced (Figure [2](#F2){ref-type="fig"}B).

To determine whether down-regulation of EZH2 can explain, at least in part, the observed inhibitory effect of melatonin on GSCs, we knocked down EZH2 in the GSC~U251~ by introducing a GV248 vector of EZH2 shRNA. The results showed that depletion of EZH2 inhibited viability as well as self-renewal of the GSC~U251~ (Figures S1A and S1B). Meanwhile, CD133, the important GSC marker was also down-regulated (Figure [S1](#SM1){ref-type="supplementary-material"}C), all in consistency with the changes of GSCs treated with the effective concentrations of melatonin. On the other hand, when EZH2 was up-regulated in the GSC~U251~, the proliferative and self-renewal abilities of these cells were elevated (Figures [2](#F2){ref-type="fig"}C and 2D, lane2). A similar result was manifested with the mRNA level of CD133 (Figure [2](#F2){ref-type="fig"}E, lane2). More importantly, 1mM melatonin lowered GSC viability or self-renewal to a comparable level in both control and EZH2-overexpressed cells (Figures [2](#F2){ref-type="fig"}C and 2D, lane3,4). Likewise, the mRNA expression of CD133 were significantly reduced (Figure [2](#F2){ref-type="fig"}E, lane3,4). Collectively, these data suggested that EZH2 was not only required for the maintenance of GSCs, but also involved in the inhibitory role of melatonin in regulation of GSC properties.

*NOTCH1* Was an EZH2 Target Gene Involved in the Effects of Melatonin
---------------------------------------------------------------------

Global gene expression profile changes were analyzed in the GSC~U251~ knockdown of EZH2. Interestingly, *NOTCH1* was one of the most significantly down-regulated genes which correlated with EZH2 depletion as evidenced by a 2.7-fold decrease in transcripts (unpublished data). As it is well established that NOTCH signaling plays a critical role in controlling GSC survival and multi-potency[@B24], [@B25], we speculated that NOTCH1 is involved in the EZH2-mediated effects of melatonin in the GSCs. To test this idea, qRT-PCR was performed in the GSC~U251~ and GSC~T98G~ to assess the mRNA expressions of NOTCH family and NOTCH signaling pathway genes. The results showed that melatonin most significantly reduced mRNA expression of NOTCH1 in both of the GSCs compared with other NOTCH receptors. NOTCH1 signaling pathway components, such as *CCND1*, *CCNE2* and *HES1*, were also deregulated (Figure [3](#F3){ref-type="fig"}A). Consistently, immunoblot analysis showed that the expressions of NOTCH intracellular domain 1 (NICD1) and HES1 were remarkably decreased when EZH2 was inhibited by melatonin (Figure [3](#F3){ref-type="fig"}B).

To further address whether NOTCH1 signaling is indeed regulated by EZH2 in the GSCs, dual-luciferase reporter assay was performed. As the result shown in Figure [3](#F3){ref-type="fig"}C, a notable reduction in the luciferase activity of *NOTCH1* promoter region was coupled with knockdown of endogenous EZH2, whereas up-regulation of EZH2 in the GSC~U251~ increased *NOTCH1* transcriptional activity (Figure [3](#F3){ref-type="fig"}C). A comparable result was observed in the GSC~T98G~ (data not shown), confirming a positive role of EZH2 in *NOTCH1* trans-activation. Moreover, immunoblot detected significant inhibition of NICD1 and HES1 protein levels in the GSCs depleted of EZH2. Over-expression of EZH2, on the other hand, resulted in an opposite effect, suggesting a functional control of EZH2 over NOTCH1 activity (Figure [3](#F3){ref-type="fig"}D).

We next asked the specific mechanism of EZH2 in *NOTCH1* trans-activation. Chromatin immunoprecipitation(ChIP) assay was conducted in the GSC~U251~ by using the antibodies detecting EZH2, tri-methylation of histone 3 at lysine 27 (H3K27me3) or suppressor of zeste 12 (SUZ12), another key component of Polycomb Repressive Complex 2 (PRC2). Interestingly, significant enrichment for endogenous EZH2 protein was detected at the *NOTCH1* promoter, which, however, can be blocked with the addition of 1mM melatonin. In contrast, no detection of H3K27me3 or SUZ12 occurred at the promoter region of *NOTCH1* (Figure [3](#F3){ref-type="fig"}E). These data indicated that EZH2 may function through directly binding to the *NOTCH1* promoter in the GSCs and this effect is independent of H3K27me3 or PRC2.

Clinical Relevance Existed between EZH2 and NOTCH1 Activation
-------------------------------------------------------------

To probe for evidence of clinical relevance between EZH2 and NOTCH1 activation, 67 GBM specimens and 12 normal human brain tissues were analyzed for the expressions of EZH2 and NOTCH intracellular domain 1 (NICD1) by immuno-histochemistry (IHC). The results showed that remarkable up-regulation of these two proteins was noted in 37 (EZH2) or 34 (NICD1) of 67 GBM specimens compared to normal brain specimens (P\<0.01; Figure [4](#F4){ref-type="fig"}A), among which 73% of the EZH2^high^ specimens were also NICD1^high^( P\< 0.001; Figure [4](#F4){ref-type="fig"}B). Additionally, there was significant positive correlation between expressions of EZH2 and NICD1, evidently supporting NOTCH1 a potential target of EZH2 in human GBMs (Figure [4](#F4){ref-type="fig"}C).

Discussion
==========

In view of the potent tumor-propagation capacity of GSCs, GSCs-targeted therapies have attracted increasing attention in recent years[@B26]-[@B28]. Here, we show that melatonin inhibited GSCs viability and self-renewal accompanied by a decrease in the expression of stem cell markers. Furthermore, we found a reduction in the expression levels of EZH2 and NOTCH1 signaling pathway components, therefore adding a new perspective to interpret the anti-tumor effects of melatonin.

EZH2 is an important epigenetic regulator that is implicated in the maintenance of tumor stem cells. It was reported that overexpression of EZH2 is frequently observed in malignant gliomas and GSCs[@B15]. Inhibition of EZH2 disrupted the morphological conversion and impaired tumorigecity of the GSCs in NOD-SCID mice[@B17]. In this study, we demonstrated that EZH2 expression is correlated with GSC propagation, self-renewal as well as GSC marker expression, providing further direct evidence for the function of EZH2 in modulating the "stemness" of the GSCs. More strikingly, melatonin lowered GSC viability or self-renewal to a comparable level in both control and EZH2-overexpressed cells. A similar result was manifested with the expression level of CD133, suggesting that the effects exerted by melatonin in the GSCs was, at least in part, dependent on EZH2 expression.

To probe for the downstream target of EZH2 in the melatonin-mediated effects, SAGE database analysis of potential EZH2 target genes were examined. *NOTCH1* was one of the most significantly down-regulated genes. Coincidentally, melatonin remarkably reduced *NOTCH1*in the GSCs as well as other NOTCH1 signaling pathway components (e.g. *CCND1*, *CCNE2* and *HES1*), which are regulated by NOTCH1*.*The active NOTCH1 protein segment, NOTCH intracellular domain 1 (NICD1) was also deregulated, suggesting that NOTCH1 might mediate the effects of EZH2 upon treatment of melatonin.

We next asked the specific mechanism of EZH2 in *NOTCH1*trans-activation. Substantial studies have indicated that EZH2 usually functions via transcriptional repression through its histone methylation activity on H3K27. For instance, biological interconversion between GSCs and differentiated non-GSCs is associated with the gain or loss of EZH2/PRC2-mediated tri-methylation of histone 3 at lysine 27 (H3K27me3) on pluripotent or development-associated genes (e.g. *NANOG*, *WNT1*, *BMP5*)[@B29]. Given the high divergent effects of EZH2 depending on context and tumor cell-type specificities, more studies began to reveal a H3K27me3-independent role of EZH2 in the GSCs. Suvà et al. reported that C-MYC was a downstream target of EZH2 by direct binding to *C-MYC* promoter via SUZ12 [@B17]. Kim et al. stated that AKT-mediated phosphorylation at S21 in EZH2 facilitated STAT3 methylation, resulting in increased tyrosine phosphorylation and activation of STAT3 in the GSCs[@B3], [@B30]. In our study, we found that EZH2 regulated NOTCH1 expression by directly interacting with the *NOTCH1* promoter. This result is consistent with the H3K27me3-independent effects of EZH2 in the above studies and suggested a specific mechanism for melatonin in the anti-GSCs effects. Furthermore, significant correlation between the expressions of EZH2 and NOTCH intracellular domain 1 (NICD1) was observed in the tumor samples from GBM patients, evidently supporting the existence of EZH2-NOTCH1 signaling pathway in the malignant gliomas.

In conclusion, this study demonstrated that melatonin, a tumor inhibitor, performs its function partly by regulating GSC properties through EZH2-NOTCH1 signaling axis. As for the clinical application of melatonin in GBM, the concentration applied in vitro is much higher than the concentration given to patients. So the effective concentration could be achieved through local drug delivery, which need further study in future.
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![**Melatonin Inhibited Viability and Self-renewal Ability of GSCs.**(**A**) The representative images of the GSC~U251~ and GSC~T98G~ (400×). (**B**) mRNA expression levels of CD133 and SOX2 were determined by qRT-PCR in the GSC~U251~ and GSC~T98G~ and the original cell lines. Data were presented as mean ± SD from three independent experiments. \**P* \< 0.05, \*\**P*\< 0.01vs. control. (**C**) The GSC~U251~ and GSC~T98G~ were treated with 0, 100nM, 100μM, 1mM melatonin for 48 hr. Cell viability was determined by CCK-8 assay. Data were presented as mean ± SD from three independent experiments. \**P*\< 0.05, \*\**P*\< 0.01 vs. results of the control w/o melatonin. (**D**) Morphological changes were shown in the GSC~U251~ and GSC~T98G~ treated with 0, 100μM, 1mM melatonin for 10 days (200×). Tumor-sphere numbers were calculated. Data were presented as mean ± SD from three independent experiments. \**P*\< 0.05, \*\**P*\< 0.01 vs. results of the control w/o melatonin.](ijbsv13p0245g001){#F1}

![**EZH2 Was Involved in the Inhibitory Role of Melatonin in Regulation of GSC Properties.** mRNA (**A**) and protein (**B**) levels of CD133, SOX2 and EZH2 were shown in the GSC~U251~ and GSC~T98G~ treated with 1mM melatonin for 48 hr. Each bar represents mean ± SD from three independent experiments. \**P*\< 0.05, \*\**P*\< 0.01 vs. control. (**C**) The GSC~U251~transfected with GV230-EZH2 (EZH2) or GV230 alone (Con) were treated with 0, 1mM melatonin for 48 hr. Cell viability was determined by CCK-8 assay. Data were presented as mean ± SD from three independent experiments. \**P*\< 0.05, \*\**P*\< 0.01. (**D**) The changes of morphology and tumor-sphere numbers were shown in the indicated cells (200×). Each bar represents mean ± SD from three independent experiments. \*\**P*\< 0.01. (**E**) mRNA levels of CD133 were determined by qRT-PCR in the indicated cells. The result represents mean ± SD from three independent experiments. \**P*\< 0.05, \*\**P*\< 0.01.](ijbsv13p0245g002){#F2}

![***NOTCH1* Was an EZH2 Target Gene Involved in the Effects of Melatonin.** (**A**) The GSC~U251~ and GSC~T98G~ were treated with 1mM melatonin for 48 hr. mRNA expression levels of NOTCH family and NOTCH signaling pathway genes were determined by qRT-PCR. Data were presented as mean ± SD from three independent experiments. \**P*\< 0.05 vs. control. (**B**) Protein levels of EZH2, NICD1 and HES1 were analyzed by immunoblot in the GSC~U251~ and GSC~T98G~ treated with 1mM melatonin for 48 hr. β-ACTIN served as a loading control. (**C**) The GSC~U251~ were transfected with pGL2-*NOTCH1*; a vector-encoding EZH2-shRNA (shEZH2) or scrambled-shRNA (shSC), or a vector-encoding wild-type EZH2 (EZH2) or its comparative control (Con); and pSV-Renilla. Values in graphs represent mean of FLuc:RLuc activity ± SD performed in triplicate. \**P*\< 0.05 vs. control. (**D**) Protein levels of NOTCH intracellular domain 1(NICD1) and HES1 were examined by immunoblot in the EZH2 depleted (shEZH2) or over-expressed (EZH2) GSCs. β-ACTIN was used as a loading control. (**E**) The GSC~U251~ were treated with 0, 1mM melatonin for 48 hr. ChIP analysis was performed by using antibodies against EZH2, tri-methylation of histone 3 at lysine 27 (H3K27me3) or suppressor of zeste 12 (SUZ12) with primers targeted to the promoter region of *NOTCH1*. Isotype matched IgG was used as a negative control. Data are presented as mean ± SD from three independent experiments. \**P*\< 0.05, *\*\*P*\<0.01 vs. control.](ijbsv13p0245g003){#F3}

![**Clinical Relevance Existed between EZH2 and NOTCH1 Activation.**(**A**) IHC was performed to detect EZH2 and NOTCH intracellular domain 1(NICD1) levels in the GBM specimens and samples of normal brain specimens (400×). (**B**) Distribution of EZH2 and NICD1 expression in 67 GBM specimens. (P \< 0.001). (**C**) Correlation between expression of EZH2 and NICD1 in 67 GBM specimens (*P*\< 0.01).](ijbsv13p0245g004){#F4}

###### 

Oligonucleotide primers used for real-time PCR.

  Gene       Forward Primer                      Reverse Primer
  ---------- ----------------------------------- -----------------------------------
  *EZH2*     5\'-TTGTTGGCGGAAGCGTGTAAAATC-3\'    5\'-TCCCTAGTCCCGCGCAATGAGC -3\'
  *NOTCH1*   5\'-AAGCTGCATCCAGAGGCAAAC-3\'       5\'-TGGCATACACACTCCGAGAACAC-3\'
  *NOTCH2*   5\'-GTTACAGCAGCCCTTGCCTGA-3\'       5\'-CCATGGATACAAGGGTTACTTGCAC-3\'
  *NOTCH3*   5\'-ATCGGCTCGGTAGTAATGCTG-3\'       5\'-ACAACGCTCCCAGGTAGTCA-3\'
  *NOTCH4*   5\'-TGCGAGGAAGATACGGAGTG-3\'        5\'-GGACGGAGTAAGGCAAGGAG-3\'
  *CCND1*    5\'-GGGCCACTTGCATGTTCGT-3\'         5\'-CAGGTTCCACTTGAGCTTGTTCAC-3\'
  *CCNE1*    5\'-CCGGTATATGGCGACACAAGA-3\'       5\'-CAAACTGGTGCAACTTTGGAG-3\'
  *CCNE2*    5\'-TGGGAACTTTGTCCTGTAACAATVA-3\'   5\'-CACAAGGCAGCAGCAGTVAGTA-3\'
  *CTNNB1*   5\'-GAGTGCTGAAGGTGCTATCTGTCT-3\'    5\'-GTTCTGAACAAGACGTTGACTTGGA-3\'
  *DVL2*     5\'-GACATGAACTTTGAGAACATGAGC-3\'    5\'-CACTTGGCCACAGTCAGCAC-3\'
  *HES1*     5\'-GGACATTCTGGAAATGACAGTGA-3\'     5\'-AGCACACTTGGGTCTGTGCTC-3\'
  *CD133*    5\'-AGTGGCATCGTGCAAACCTG-3\'        5\'-CTCCGAATCCATTCGACGATA-3\'
  *SOX2*     5\'-GTGAGCGCCCTGCAGTACAA-3\'        5\'-GCGAGTAGGACATGCTGTAGGTG-3\'
  *GAPDH*    5\'-GCACCGTCAAGGCTGAGAAC-3\'        5\'-TGGTGAAGACGCCAGTGGA-3\'
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